TPST vs. LFVN, AFMD, HOOK, LPTX, JAGX, CRVS, RVPH, ANEB, CNTB, and SLS
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include LifeVantage (LFVN), Affimed (AFMD), Hookipa Pharma (HOOK), Leap Therapeutics (LPTX), Jaguar Health (JAGX), Corvus Pharmaceuticals (CRVS), Reviva Pharmaceuticals (RVPH), Anebulo Pharmaceuticals (ANEB), Connect Biopharma (CNTB), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical preparations" industry.
Tempest Therapeutics (NASDAQ:TPST) and LifeVantage (NASDAQ:LFVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
In the previous week, Tempest Therapeutics had 3 more articles in the media than LifeVantage. MarketBeat recorded 10 mentions for Tempest Therapeutics and 7 mentions for LifeVantage. LifeVantage's average media sentiment score of 0.77 beat Tempest Therapeutics' score of 0.15 indicating that LifeVantage is being referred to more favorably in the news media.
Tempest Therapeutics has a beta of -1.65, suggesting that its stock price is 265% less volatile than the S&P 500. Comparatively, LifeVantage has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.
LifeVantage has a net margin of 1.75% compared to Tempest Therapeutics' net margin of 0.00%. LifeVantage's return on equity of 27.02% beat Tempest Therapeutics' return on equity.
LifeVantage received 128 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 77.82% of users gave LifeVantage an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
LifeVantage has higher revenue and earnings than Tempest Therapeutics. Tempest Therapeutics is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 35.3% of LifeVantage shares are owned by institutional investors. 3.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 6.8% of LifeVantage shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Tempest Therapeutics presently has a consensus price target of $25.00, indicating a potential upside of 669.23%. Given Tempest Therapeutics' higher possible upside, equities analysts clearly believe Tempest Therapeutics is more favorable than LifeVantage.
Summary
LifeVantage beats Tempest Therapeutics on 13 of the 16 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
